ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2016

Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis

Masayoshi Harigai1, Ryoko Sakai 2, Takahiko Sugihara 3 and Akihito Ishigami 4, 1Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Tokyo Medical and Dental University, Tokyo, Japan, 4Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: citrullination, genetics and neutrophils, pathogenesis, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Peptidyl-arginine deiminases (PADIs) are enriched in neutrophils and considered to be responsible for citrullination of proteins in vivo. Autoantibody against citrullinated proteins are frequently detected in patients with rheumatoid arthritis (RA) and are highly diagnostic for the disease. PADI activity is detected in synovial fluid, and citrullinated proteins are found in synovium of patients with RA. Genetic evidence has shown that single nucleotide variants (SNVs) of PADI2 and PADI4 genes are associated with RA susceptibility. We aimed to elucidate association of SNVs of PADIs and their expression in peripheral blood neutrophils from patients with RA.

Methods: We enrolled 23 patients who fulfilled the 2010 American College of Rheumatology / European League Against Rheumatism classification criteria for RA and 20 healthy controls. Peripheral blood neutrophils were separated by using magnetic beads and applied to in vitro culture and extraction of genomic DNA. Neutrophils were cultured with or without stimulation for 48 hours and supernatants were collected to measure PADI2 and PADI4 by using enzyme-linked immunosorbent assay. SNVs of PADI2 and PADI4 were determined by using TaqMan SNP Genotyping Assays. Quantitative real-time RT-PCR was used to measure mRNA levels of PADI2 and PADI4.

Results: Fresh neutrophils from patients with RA expressed significantly larger amounts of PADI2 (p = 0.001) and PADI4 (P = 0.003) mRNA, than healthy controls (Figure 1). Neutrophils spontaneously released PADI2 and PADI4. Upon stimulation with PMA (20 and 200 microM), secretion of PADI2 significantly increased in patients with RA (p = 0.003 for 20 microM; p = 0.001 for 200 microM), but not in healthy controls. On the contrary, secretion of PADI4 significantly decreased in healthy controls at both PMA concentrations (p = 0.001 for 20 microM; p = 0.003 for 200 microM), but only at 20 microM in patients with RA (p = 0.05 for 20 microM, p = 0.5 at 200 microM). Patients and healthy controls were stratified by numbers of risk allele in SNVs of PADI genes, and mRNA levels of PADIs were compared (Figure 2). Multiple linear regression analyses revealed that RA (versus healthy controls) [nonstandardized partial regression coefficient (NPRC) = 1.29, 95% confidence interval (95% CI) 0.67 – 1.91, p = 0.001] and numbers of the risk allele of PADI2 rs761426 (A – >T) (NPRC = 0.20, 95% CI = 0.010 – 0.39, p = 0.04) were significantly associated with the levels of PADI2 mRNA in neutrophils. RA (versus healthy controls) was also associated with the levels of PADI4 mRNA in neutrophils (NPRC = 0.95, 95% CI = 0.36 – 1.55, p = 0.002), but not numbers of the risk allele of PADI4 rs11203367 (C – >T).

Conclusion: Expression levels of PADI2 and PADI4 mRNA were higher in patients with RA compared to healthy controls, but their association with SNVs are different. Secretion of these PADIs upon stimulation with PMA were different, which may suggest their independent physiological and pathological roles in vivo.


Figure1_2019.06.03

Peripheral blood neutrophils were separated by using magnetic beads and total RNA was extracted. PADI2 and PADI4 mRNA were measured by using real-time RT-PCR and normalized by beta-actin mRNA.


Figure2_2019.06.03

Patients and healthy controls were stratified by numbers of risk allele of the PADI2 or PADI4 single nucleotide variant, and mRNA levels of PADIs were compared across the groups.


Disclosure: M. Harigai, AbbVie Japan GK, 2, 8, Ayumi Pharmaceutical Co. Ltd., 2, Bristol Meyers Squib, 2, 5, 8, Bristol-Myers Squibb Co. Ltd, 2, 5, 8, Chugai Pharmaceutical Co. Ltd., 2, 5, 8, Chugai Pharmaceutical Co., Ltd., 2, 5, 8, Eisai Co. Ltd., 2, Eisai Co., Ltd., 2, Eli Lilly, 5, 8, Mitsubishi Tanabe Pharma Co., 2, Mitsubishi Tanabe Pharma Corp., 2, Nippon Kayaku Co. Ltd., 2, Taisho Toyama Pharmaceutical Co. Ltd., 2, Takeda Pharmaceutical Co., 2, Takeda Pharmaceutical Co., Ltd., 2, Teijin Pharma Ltd., 2, 8, Teijin Pharma, Ltd., 2, 8; R. Sakai, Ayumi Pharmaceutical Co. Ltd., 2, Bristol Meyers Squib, 2, Chugai Pharmaceutical Co. Ltd., 2, Mitsubishi Tanabe Pharma Corp., 2, Nippon Kayaku Co. Ltd., 2, Taisho Toyama Pharmaceutical Co. Ltd., 2; T. Sugihara, Ayumi Pharmaceutical, 9, Ayumi Pharmaceutical Corporation, 2, Chugai Pharmaceutical, 9, Chugai Pharmaceutical Co., Ltd., 2, CSL Behring, 9, CSL Behring K.K., 2, Japan Blood Products Organization, 2, 9, UCB Japan, 9, UCB Japan Co. Ltd., 2; A. Ishigami, None.

To cite this abstract in AMA style:

Harigai M, Sakai R, Sugihara T, Ishigami A. Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/expression-of-peptidyl-arginine-deiminases-in-peripheral-blood-neutrophils-and-its-association-with-single-nucleotide-variants-in-patients-with-rheumatoid-arthritis/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-peptidyl-arginine-deiminases-in-peripheral-blood-neutrophils-and-its-association-with-single-nucleotide-variants-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.